Dr John C Byrd physician scientist who has done translational and clinical drug development for two decades. My laboratory and clinical work has directly resulted in 4 drugs getting FDA approval. This experience bridges close interaction with industry as a consultant to develop and implement a successful development plan (Calistoga, Idelalisib) to performing pre-clinical and clinical work in my University role focused on a single class of drugs that transformed the care of CLL (Ibrutinib, Acalabrutinib) and other B-cell malignancies.
+44 1300 500008